Recordati offer reaches 74.58 percent: Recordati stock sits 0.06 percent above EUR 53.00 bid

Published on 10/26/2026 at 11:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The offer reached 74.58 percent on October 26, 2026. Recordati stock costs EUR 53.03 against the EUR 53.00 bid before reopening November 3, 2026.

Offer process sets next dates

Respighi BidCo's Recordati offer reached 74.58 percent on October 26, 2026.
The improved offer price is EUR 53.00 per share after October 6, 2026.
Recordati stock trades at EUR 53.03 at 10:57 a.m. CEST at Lang & Schwarz on October 26, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte, Tabletten und Stethoskop auf Holztisch — Recordati S.p.A. (IT0003828271) symbolisiert dieses Flatlay mit Aktienzertifikat, ISIN-Karte und typischen Pharma-Utensilien, Illustration mit AI erstellt.

Recordati (IT0003828271) was trading at EUR 53.03 at Lang & Schwarz on October 26, 2026 at 10:57 a.m. CEST. MarketScreener reported that Respighi BidCo and its CVC and GBL investors reached a combined 74.58 percent stake after the offer period ended on October 23, 2026.

Offer clears the minimum threshold

The result exceeds the 66.67 percent minimum required for the offer to become effective. About 130.00 million shares were tendered for a total value of EUR 6.89 billion, while the offer price stands at EUR 53.00 per share including the dividend, according to MarketScreener.

The chronology shows how the transaction reached this point. On October 6, 2026, Respighi BidCo raised the offer to EUR 53.00 per share, according to MarketScreener. On October 23, 2026, the acceptance period ended with the offer reaching its decisive stage. On October 26, 2026, the reported combined stake stood at 74.58 percent.

What does 74.58 percent mean?

The threshold result gives the bidder a path toward a possible delisting, but the next structural hurdle is 90.00 percent. If that level is not reached, the offer documents provide for further procedures tied to a merger and potential shareholder withdrawal, as MarketScreener reported.

Recordati's operating backdrop remains measurable. In the second quarter of 2026, revenue reached EUR 697.40 million, up 8.30 percent from the second quarter of 2025, while net income rose 28.00 percent to EUR 116.60 million, according to Simply Wall St. Recordati says it develops medicines for common and rare diseases and operates in around 150 countries, according to its investor-relations page.

Dates shape the delisting path

Payment for shares tendered during the initial period is scheduled for November 2, 2026. The offer is due to reopen from November 3 through November 9, 2026, with payment for those acceptances scheduled for November 17, 2026, according to MarketScreener. Recordati's next results are listed for November 10, 2026.

Stock stays near the offer price

The Lang & Schwarz quote is EUR 53.03, or 0.06 percent above the EUR 53.00 offer price. The small premium keeps the tender terms central to the stock's near-term valuation.

The further course of trading is shown by the continuously updated real-time quote of Recordati stock.